-
Hematology/oncology Clinics of North... Feb 2019Primary cutaneous B-cell lymphomas are non-Hodgkin lymphomas that present in the skin without evidence of extracutaneous involvement at diagnosis. There are 3 types of... (Review)
Review
Primary cutaneous B-cell lymphomas are non-Hodgkin lymphomas that present in the skin without evidence of extracutaneous involvement at diagnosis. There are 3 types of primary cutaneous B-cell lymphomas: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg-type. Because it is most frequently diagnosed on skin biopsy, intravascular large B-cell lymphoma is commonly included with pcBCL. A complicating factor in diagnosing primary cutaneous B-cell lymphomas is that they can appear histologically identical to their extracutaneous counterparts. This review summarizes the clinical presentation, histopathology, evaluation, treatment, and differential diagnosis of these lymphomas.
Topics: Biopsy; Diagnosis, Differential; Disease Management; Disease Susceptibility; Humans; Immunohistochemistry; Lymphoma, B-Cell; Neoplasm Staging; Prognosis; Skin; Skin Neoplasms
PubMed: 30497672
DOI: 10.1016/j.hoc.2018.08.006 -
Nature Reviews. Cancer Apr 2005Chromosomal translocations involving the immunoglobulin loci are a hallmark of many types of B-cell lymphoma. Other factors, however, also have important roles in the... (Review)
Review
Chromosomal translocations involving the immunoglobulin loci are a hallmark of many types of B-cell lymphoma. Other factors, however, also have important roles in the pathogenesis of B-cell malignancies. Most B-cell lymphomas depend on the expression of a B-cell receptor (BCR) for survival, and in several B-cell malignancies antigen activation of lymphoma cells through BCR signalling seems to be an important factor for lymphoma pathogenesis. Recent insights into the lymphomagenic role of factors supplied by the microenvironment also offer new therapeutic strategies.
Topics: Cell Communication; Genes, Immunoglobulin; Genes, Tumor Suppressor; Germinal Center; Humans; Lymphoma, B-Cell; Mutation; Receptors, Antigen, B-Cell; Signal Transduction; Translocation, Genetic
PubMed: 15803153
DOI: 10.1038/nrc1589 -
Giornale Italiano Di Dermatologia E... Aug 2019Primary cutaneous B-cell lymphomas comprehend a group of lymphoproliferative disorders characterized by being monoclonal proliferations of B-cell primarily involving the... (Review)
Review
Primary cutaneous B-cell lymphomas comprehend a group of lymphoproliferative disorders characterized by being monoclonal proliferations of B-cell primarily involving the skin. Despite being recognized as autonomous and distinct clinico-pathologic entities since the late 80s, their classification is still an ongoing matter of debate. At the moment, WHO classification recognizes three disorders: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma and primary cutaneous diffuse large b-cell lymphoma (leg type). Primary cutaneous diffuse large b-cell lymphoma (other) has been used to define rare cases which show histologically an infiltrate with diffuse pattern composed by large b-cell, but not fitting with criteria for follicle center lymphoma nor for primary cutaneous diffuse large b-cell lymphoma (leg type). Aim of this review was to briefly describe all recognized and provisional entities included in the primary cutaneous b-cell lymphomas and to discuss recent acquisitions that may influence their future classifications.
Topics: Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Skin Neoplasms
PubMed: 29144099
DOI: 10.23736/S0392-0488.17.05670-X -
Revue Medicale Suisse Apr 2014Primary cutaneous B-cell lymphomas (PCBCL) present as skin lesions without evidence of extracutaneous involvement at diagnosis. This article summarizes clinical and... (Review)
Review
Primary cutaneous B-cell lymphomas (PCBCL) present as skin lesions without evidence of extracutaneous involvement at diagnosis. This article summarizes clinical and histopathological features of the three main types of PCBCL: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma and primary cutaneous diffuse large B-cell lymphoma, leg type. It will discuss initial staging procedures, necessary to differentiate PCBCL from systemic lymphoma with secondary skin involvement. Finally, we will review the main treatments, local therapy (radiotherapy, surgical excision) for indolent PCBCL and multiagent chemotherapy for primary cutaneous diffuse large B-cell lymphoma, leg type.
Topics: Biopsy; Diagnostic Imaging; Humans; Lymphoma, B-Cell; Molecular Diagnostic Techniques; Neoplasm Staging; Skin Neoplasms
PubMed: 24772806
DOI: No ID Found -
Expert Review of Hematology Jul 2019: High Grade B-cell Lymphomas (HGBL) have been defined as a new separate entity in 2016 revised WHO classification of lymphoid neoplasms. The previously well-known... (Review)
Review
: High Grade B-cell Lymphomas (HGBL) have been defined as a new separate entity in 2016 revised WHO classification of lymphoid neoplasms. The previously well-known Double- and Triple-Hit Lymphomas (DHL/THL) are included in this umbrella category under the name of HGBL with and and/or rearrangements (HGBL, R). A comprehensive diagnosis of HGBL is laborious, the diagnostic analyses required are expensive and time-consuming; moreover, a uniform consensus on which patients should be investigated has not been reached yet. Furthermore, there is no agreement on a standard therapeutic approach for this entity. : In this article, the biological and clinical peculiarities of HGBL will be reviewed and all tools for a comprehensive diagnosis as well as the current therapeutic landscape will be investigated. : HGBL, R remains a challenging disease in terms of diagnosis and further research should be performed in order to define clear guidelines determining which cases have to be investigated thoroughly with FISH and other probes. Unsatisfying results have been shown in patients with HGBL, R treated with intensified chemoimmunotherapy strategies, therefore, larger prospective clinical trials should be conducted. Investigation into novel drugs that could lead to improvement of the current therapeutic approach should also be addressed.
Topics: Biomarkers, Tumor; Biopsy; Combined Modality Therapy; Disease Management; Disease Progression; Disease Susceptibility; Drug Resistance, Neoplasm; Genetic Predisposition to Disease; Genetic Testing; Humans; Immunohistochemistry; Lymphoma, B-Cell; Neoplasm Grading; Prognosis; Recurrence; Symptom Assessment; Treatment Outcome
PubMed: 31150587
DOI: 10.1080/17474086.2019.1624157 -
The Malaysian Journal of Pathology Apr 2024Lymphomas are a diverse group of malignant proliferations that arise as discrete tissue masses. The most widely accepted taxonomy for lymphoma is the World Health... (Review)
Review
Lymphomas are a diverse group of malignant proliferations that arise as discrete tissue masses. The most widely accepted taxonomy for lymphoma is the World Health Organization classification of tumours of haematopoietic and lymphoid tissues, the 5th edition of which was released in June 2022. Most (85% to 90%) lymphoid neoplasms are of B cell origin. Mature B-cell neoplasms are a heterogeneous group of malignancies with similar disease courses and treatment paradigms. This review focuses on the various mature B-cell lymphomas in Malaysia, including Hodgkin lymphoma. A literature search was performed in various bibliographic databases. A total of 64 papers were included in this review. We found 15 papers on Hodgkin lymphoma, 14 on follicular lymphoma, 12 on Burkitt lymphoma, 5 on mucosa-associated lymphoid tissue (MALT) lymphoma, 4 on plasmablastic lymphoma, 3 on mantle cell lymphoma, 1 each on primary mediastinal large B-cell lymphoma, B-lymphoblastic lymphoma, and 3 on other unspecified B-cell lymphomas. The site, age, distribution, prognostic markers, and the various subclassification of B cell lymphomas were studied from these papers. Prognostic genetic markers in B-cell lymphomas include C-MYC, BCL2 and BCL6 as they are the most prevalent mutations in this condition. Anecdotal outcomes range from rapid fatality to unexplained spontaneous remission. This review adds to the existing literature on lymphoma in Malaysia by compiling the evidence that may lead to further research on the diagnosis and treatment of lymphoma in Malaysia and worldwide.
Topics: Humans; Lymphoma, B-Cell; Malaysia; Biomedical Research
PubMed: 38682841
DOI: No ID Found -
Cancer Letters Oct 2017MicroRNAs (miRNAs) are small non-coding RNAs that regulate many human genes including those involved in normal B-cell development. When these miRNAs are aberrantly... (Review)
Review
MicroRNAs (miRNAs) are small non-coding RNAs that regulate many human genes including those involved in normal B-cell development. When these miRNAs are aberrantly expressed in B-cells they play key pathogenetic roles in the development and maintenance of B-cell lymphomas and by association may serve as useful biomarkers. In this review, we provide an overview of the importance of miRNAs to B-cell lymphomagenesis, as well as considering their use as biomarkers, and their potential usefulness for the clinic.
Topics: Biomarkers, Tumor; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, B-Cell; MicroRNAs
PubMed: 28757417
DOI: 10.1016/j.canlet.2017.07.020 -
Expert Review of Hematology Feb 2017Mature B-cell lymphoma represents the most common type of Non-Hodgkin lymphoma, and different subtypes prevail at different patient ages. Areas covered: We review recent... (Review)
Review
Mature B-cell lymphoma represents the most common type of Non-Hodgkin lymphoma, and different subtypes prevail at different patient ages. Areas covered: We review recent data on differences and commonalities in mature B-cell lymphoma occurring in adult and pediatric patients, with a special emphasis on molecular advances and therapeutic implications. To this end, we will discuss knowledge on diffuse large B-cell lymphoma and Burkitt lymphoma/leukemia, which are the most frequent subtypes in adult and pediatric patients, respectively, and on primary mediastinal B-cell lymphoma, which is a subtype of mature B-cell lymphoma occurring mainly in adolescents and young adults with a female predominance. Expert commentary: Molecular profiling has revealed molecular alterations that can be used to further classify the subtypes of mature B-cell lymphoma. These new subgroups frequently respond differentially to targeted therapeutic strategies. Future clinical trials utilizing new drugs will address this issue by combining clinical data and response assessment with a molecular workup of the corresponding lymphomas.
Topics: Age Factors; Cell Transformation, Neoplastic; Combined Modality Therapy; Diagnosis, Differential; Disease Progression; Humans; Lymphoma, B-Cell; Neoplasm Grading; Prognosis; Standard of Care; Treatment Outcome
PubMed: 27936978
DOI: 10.1080/17474086.2017.1271318 -
American Journal of Clinical Pathology Apr 1993Monocytoid B-cell lymphoma is a distinct clinicopathologic entity occurring primarily in the lymph nodes of elderly patients. Its unique features compared with other... (Review)
Review
Monocytoid B-cell lymphoma is a distinct clinicopathologic entity occurring primarily in the lymph nodes of elderly patients. Its unique features compared with other low-grade lymphomas are also its characteristic morphologic features. These are its rare leukemic conversion and infrequent bone marrow involvement, and its relatively common association with autoimmune disease. Although MBCL is believed to be a low-grade, indolent type of lymphoma, its progression to high-grade lymphoma warrants close follow-up of patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diagnosis, Differential; Female; Humans; Lymphoid Tissue; Lymphoma, B-Cell; Male; Middle Aged
PubMed: 8475908
DOI: 10.1093/ajcp/99.4.421 -
Haematologica Feb 2014B-cell lymphomas comprise an increasing number of clinicopathological entities whose characterization has historically been based mainly on histopathological features.... (Review)
Review
B-cell lymphomas comprise an increasing number of clinicopathological entities whose characterization has historically been based mainly on histopathological features. In recent decades, the analysis of chromosomal aberrations as well as gene and miRNA expression profile studies have helped distinguish particular tumor types and also enabled the detection of a number of targets with therapeutic implications, such as those activated downstream of the B-cell receptor. Our ability to identify the mechanisms involved in B-cell lymphoma pathogenesis has been boosted recently through the use of Next Generation Sequencing techniques in the analysis of human cancer. This work summarizes the recent findings in the molecular pathogenesis of B-cell neoplasms with special focus on those clinically relevant somatic mutations with the potential to be explored as candidates for the development of new targeted therapies. Our work includes a comparison between the mutational indexes and ranges observed in B-cell lymphomas and also with other solid tumors and describes the most striking mutational data for the major B-cell neoplasms. This review describes a highly dynamic field that currently offers many opportunities for personalized therapy, although there is still much to be gained from the further molecular characterization of these clinicopathological entities.
Topics: Chromosome Aberrations; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, B-Cell; MicroRNAs; RNA, Neoplasm
PubMed: 24497559
DOI: 10.3324/haematol.2013.096248